Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Lung Diseases, Pulmonary Disease, Chronic Obstructive
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an…
- Trial name
- NCT00132730
- Testing
- MK-0873 2.5 mg, MK-0873 1.25 mg, MK-0873 0.75 mg
- Volunteers
- 604 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD Symptoms After Coil Procedure
Chronic Obstructive Pulmonary Disease (COPD) Co-Pilot AIR Substudy of CLN0014
The purpose of undertaking CLN0020, which was a Substudy of the European Coil registry (CLN0014), was to investigate the use of COPD Co-Pilot AIR™, a COPD disease management program manufactured and operated by HGE Health Care…
- Trial name
- Co-Pilot Air (NCT03267992)
- Testing
- COPD Co-Pilot AIR App
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Disease, Chronic Obstructive
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
- Trial name
- NCT00950807
- Testing
- Tiotropium, GSK573179
- Where
- 19 sites in United States, Germany
- Volunteers
- 176 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
COPD
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT02040792
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Mylan Inc.
Asthma, COPD
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
This observational study evaluates whether lung sound analysis with LungPass device can be used to differentiate exacerbation and stable state asthma and COPD.
- Trial name
- NCT05145894
- Testing
- Lung auscultation with LungPass device (electronic auscultation)
- Where
- Belarus
- Volunteers
- 200 people
- Sponsor
- Healthy Networks
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
The primary objective of this trial is to establish superiority of the once-daily Tiotropium plus Salmeterol Inhalation Powder in daytime lung function response and non-inferiority in night-time lung function response over the…
- Trial name
- NCT00662792
- Testing
- Tiotropium (Tio18GEL), Salmeterol MDPI (Salm50DPI), Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
- Where
- 12 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of GSK961081 in Healthy Volunteer Subjects
GSK961081 is a new long-acting bronchodilator being developed for the treatment of chronic obstructive pulmonary disease (COPD). This study is the first clinical study in humans.
- Trial name
- NCT00887406
- Testing
- GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL).
- Trial name
- NCT06175065
- Testing
- RLS-0071
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- ReAlta Life Sciences, Inc.
Chronic Obstructive Pulmonary Disease, COPD
Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults
This study aims to assess the effect of EP395 against an induced inflammation of the lung. In addition, further data about the safety and tolerability of EP395 will be collected.
- Trial name
- NCT05516316
- Testing
- EP395
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- EpiEndo Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Study in Subjects Greater Than 40 Years of Age With COPD
This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study. The objectives of this study are: 1.
- Trial name
- NCT00507234
- Testing
- formoterol fumarate inhalation solution
- Where
- 19 sites in United States
- Volunteers
- 128 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease (COPD)
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to characterize the pharmacodynamic profile of Formoterol Fumarate and Foradil Aerolizer
- Trial name
- NCT01113593
- Testing
- Formoterol Fumarate, Foradil Aerolizer
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dey
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.
- Trial name
- NCT04441788
- Testing
- ION-827359
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
COPD
Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care.
- Trial name
- NCT05433961
- Testing
- MagniXene Hyperpolarized Xenon MRI
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Xemed LLC
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03570359
- Testing
- Interferon Beta-1A
- Where
- 16 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- Synairgen Research Ltd.
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Asthma
Bronchodilator Properties and Safety in Asthma
Recent large clinical studies have demonstrated the interest of LAMA therapy in the management of asthma, when compared to LABA.
- Trial name
- NCT01951222
- Testing
- V0162
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Pierre Fabre Medicament
Chronic Obstructive Pulmonary Disease
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic…
- Trial name
- NCT03414541
- Testing
- DS102
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Afimmune
COPD, Smoking
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.
The purpose of this study is to demonstrate the slowing of the disease progression including the improvement of Chronic Obstructive Pulmonary Disease (COPD) symptoms in smoking subjects with mild to moderate COPD and a history of…
- Conditions
- COPD, Smoking, Tobacco Use
- Trial name
- NCT05569005
- Testing
- THS use, Cigarette, Smoking Abstinence
- Where
- 170 sites in United States, Bulgaria and 6 more
- Volunteers
- 715 people
- Sponsor
- Philip Morris Products S.A.
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis